欧盟建议批准Dupixent®(度普利尤单抗)用于治疗持续性症状的幼童慢性自发性荨麻疹

美股速递
Feb 27

再生元制药公司研发的Dupixent®(度普利尤单抗)获得欧盟人用药品委员会积极意见,建议批准用于治疗现有疗法控制不佳的6至11岁慢性自发性荨麻疹患儿。该推荐基于III期临床试验数据,显示度普利尤单抗能显著减轻瘙痒和风团症状。若获欧盟委员会最终批准,这将是首个用于低龄儿童群体的慢性自发性荨麻疹靶向疗法。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10